Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...
Fintel on MSN19h
Morgan Stanley Downgrades Third Harmonic Bio (THRD)
Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...
Third Harmonic halting non-THB335 research, reducing workforce by 50%
In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...
Third Harmonic Bio announces Phase 1 clinical results for THB335
Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.
Wall Street Journal26d
Third Harmonic Bio Inc.
1 Day THRD 1.94% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...
Nasdaq2y
Third Harmonic Bio, Inc. Common Stock (THRD) Institutional Holdings
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...